Summary & Overview
HCPCS Level II J9328: Injection, temozolomide, 1 mg
HCPCS Level II code J9328 represents temozolomide billed at 1 mg for injectable antineoplastic therapy. Temozolomide is an oral or injectable chemotherapy agent used in oncology; billing per milligram allows granular capture of administered dose and cost. Nationally, accurate reporting of drug-specific HCPCS codes like J9328 matters for payment integrity, quality measurement, and tracking utilization of high-cost oncology agents.
Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise exposition of what J9328 represents clinically and operationally, and how it is used in claims for chemotherapy administration in outpatient infusion settings. The publication summarizes payer coverage patterns and benchmarks where available, highlights relevant billing considerations for chemotherapy dispensing and per-milligram coding, and outlines clinical context for temozolomide use.
This summary provides practical reference material for billing staff, revenue cycle leaders, and policy analysts seeking clarity on drug-level HCPCS reporting, reimbursement considerations at the national level, and the administrative context of temozolomide injections in oncology care.
Billing Code Overview
HCPCS Level II code J9328 denotes Injection, temozolomide, 1 mg. This code represents the drug temozolomide packaged for parenteral administration and billed per milligram. The service type is pharmacologic antineoplastic therapy (intravenous or oral injectable administration). The typical site of service for this medication is hospital outpatient infusion centers, oncology clinics, and infusion suites, where chemotherapy and other oncologic injections are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with newly diagnosed glioblastoma multiforme receives oral temozolomide in many regimens, but J9328 is used when temozolomide is administered by injection in hospital or clinic settings (often when an IV or parenteral formulation is used for patients who cannot tolerate oral therapy or during inpatient transitions). Typical workflow: oncology clinic schedules a chemotherapy infusion encounter; pre-visit nursing triage confirms labs and performance status; physician documents indication and chemotherapy plan in the medical record with dosing per protocol; pharmacy compounds the injectable temozolomide and dispenses a vial(s) labeled with mg; nursing verifies patient identity and consent, prepares intravenous access if needed, and administers the injection; post-administration monitoring for acute adverse events occurs in the infusion area; billing posts J9328 units by milligrams administered and appends appropriate modifiers for service circumstances (for example, JW for discarded drug waste or 59 for distinct procedural services). Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA plans, and Medicare, each with specific prior authorization and drug coverage rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|